应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
IGF 全球基础设施ETF-iShares
交易中 11-22 12:43:38 EST
55.35
+0.01
+0.02%
最高
55.54
最低
55.19
成交量
42.56万
今开
55.36
昨收
55.34
日振幅
0.63%
总市值
46.55亿
流通市值
46.55亿
总股本
8,410万
成交额
2,354万
换手率
0.51%
流通股本
8,410万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
【长春高新:下属公司获得医疗器械注册证】金十数据8月30日讯,长春高新8月30日晚间公告,近日,公司下属公司上海赛增医疗科技有限公司收到上海市药监局颁发的《医疗器械注册证》(体外诊断试剂),产品名称为胰岛素样生长因子I(IGF-I)检测试剂盒(荧光免疫层析法)。
美港电讯 · 08-30
【长春高新:下属公司获得医疗器械注册证】金十数据8月30日讯,长春高新8月30日晚间公告,近日,公司下属公司上海赛增医疗科技有限公司收到上海市药监局颁发的《医疗器械注册证》(体外诊断试剂),产品名称为胰岛素样生长因子I(IGF-I)检测试剂盒(荧光免疫层析法)。
【光大证券:信达生物(01801.HK)替妥尤单抗注射液上市申请获得受理 维持“买入”评级】智通财经APP获悉,光大证券发布研究报告称,维持信达生物(01801.
智通财经 · 05-24
【光大证券:信达生物(01801.HK)替妥尤单抗注射液上市申请获得受理 维持“买入”评级】智通财经APP获悉,光大证券发布研究报告称,维持信达生物(01801.
信达生物宣布替妥尤单抗(IGF-1R抗体)新药上市申请获国家药品监督管理局正式受理, 用于治疗甲状腺眼病
美通社 · 05-21
信达生物宣布替妥尤单抗(IGF-1R抗体)新药上市申请获国家药品监督管理局正式受理, 用于治疗甲状腺眼病
双成药业:醋酸奥曲肽注射液ANDA获得美国FDA上市许可双成药业公告,醋酸奥曲肽注射液ANDA获得美国FDA上市许可。醋酸奥曲肽注射液适用于控制手术治疗或放射治疗不能充分控制病情的肢端肥大症患者的症状并降低患者的生长激素(GH)和胰岛素样生长因子-1(IGF-1)血浆水平。
格隆汇 · 05-06
双成药业:醋酸奥曲肽注射液ANDA获得美国FDA上市许可双成药业公告,醋酸奥曲肽注射液ANDA获得美国FDA上市许可。醋酸奥曲肽注射液适用于控制手术治疗或放射治疗不能充分控制病情的肢端肥大症患者的症状并降低患者的生长激素(GH)和胰岛素样生长因子-1(IGF-1)血浆水平。
暂无数据
公司概况
公司名称:
全球基础设施ETF-iShares
所属市场:
ARCA
上市日期:
--
主营业务:
发行价格:
--
{"stockData":{"symbol":"IGF","market":"US","secType":"STK","nameCN":"全球基础设施ETF-iShares","latestPrice":55.35,"timestamp":1732297399275,"preClose":55.34,"halted":0,"volume":425580,"delay":0,"floatShares":84100000,"shares":84100000,"eps":0,"marketStatus":"交易中","marketStatusCode":2,"change":0.01,"latestTime":"11-22 12:43:38 EST","open":55.36,"high":55.54,"low":55.1891,"amount":23535540.0666,"amplitude":0.006341,"askPrice":55.36,"askSize":400,"bidPrice":55.34,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"exchange":"ARCA","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1732309200000},"adr":0,"adjPreClose":55.34,"adrRate":0,"sharesOutstanding":84100000,"nav":54.6905,"aum":4599473488.9,"bidAskSpread":0.000419,"preHourTrading":{"tag":"盘前","latestPrice":55.34,"preClose":55.34,"latestTime":"08:00 EST","volume":1,"amount":55.34,"timestamp":1732280424091},"postHourTrading":{"tag":"盘后","latestPrice":55.34,"preClose":55.34,"latestTime":"19:48 EST","volume":3,"amount":165.26,"timestamp":1732236515460},"volumeRatio":1.736615,"impliedVol":0.3033,"impliedVolPercentile":0.9841},"requestUrl":"/m/hq/s/IGF/tweets","defaultTab":"tweets","newsList":[{"id":"2463660733","title":"【长春高新:下属公司获得医疗器械注册证】金十数据8月30日讯,长春高新8月30日晚间公告,近日,公司下属公司上海赛增医疗科技有限公司收到上海市药监局颁发的《医疗器械注册证》(体外诊断试剂),产品名称为胰岛素样生长因子I(IGF-I)检测试剂盒(荧光免疫层析法)。","url":"https://stock-news.laohu8.com/highlight/detail?id=2463660733","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463660733?lang=zh_cn&edition=full","pubTime":"2024-08-30 19:20","pubTimestamp":1725016807,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0057","09997","BK1100","BK0028","BK1574","000661","BK1583","BK0046","BK0239","159891","09996","BK0075","BK1222","159883","IGF","BK0188"],"gpt_icon":0},{"id":"2437372352","title":"【光大证券:信达生物(01801.HK)替妥尤单抗注射液上市申请获得受理 维持“买入”评级】智通财经APP获悉,光大证券发布研究报告称,维持信达生物(01801.","url":"https://stock-news.laohu8.com/highlight/detail?id=2437372352","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437372352?lang=zh_cn&edition=full","pubTime":"2024-05-24 09:39","pubTimestamp":1716514772,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["01801","BK0028","IGF","601788","CDE","BK1589","BK1574","LU1969619763.USD","BK0012","BK0183","159992","BK0188","BK1161","BK1583","LU2328871848.SGD","06978","BK0276","BK4017"],"gpt_icon":0},{"id":"2437129437","title":"信达生物宣布替妥尤单抗(IGF-1R抗体)新药上市申请获国家药品监督管理局正式受理, 用于治疗甲状腺眼病","url":"https://stock-news.laohu8.com/highlight/detail?id=2437129437","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2437129437?lang=zh_cn&edition=full","pubTime":"2024-05-21 08:41","pubTimestamp":1716252060,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2024年5月21日 /美通社/ --信达生物制药集团,一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司,今日宣布:替妥尤单抗注射液的新药上市申请已获中国国家药品监督管理局药品审评中心受理,用于甲状腺眼病的治疗。期待替妥尤单抗能早日上市,造福中国TED患者。2024年5月,替妥尤单抗的首个NDA获NMPA受理,用于TED的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4419306_ZH19306_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","BK1589","BK1161","IVBIY","LU1969619763.USD","01801","IGF","LU2328871848.SGD","BK1583"],"gpt_icon":0},{"id":"2433244838","title":"双成药业:醋酸奥曲肽注射液ANDA获得美国FDA上市许可双成药业公告,醋酸奥曲肽注射液ANDA获得美国FDA上市许可。醋酸奥曲肽注射液适用于控制手术治疗或放射治疗不能充分控制病情的肢端肥大症患者的症状并降低患者的生长激素(GH)和胰岛素样生长因子-1(IGF-1)血浆水平。","url":"https://stock-news.laohu8.com/highlight/detail?id=2433244838","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2433244838?lang=zh_cn&edition=full","pubTime":"2024-05-06 16:19","pubTimestamp":1714983556,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4535","BK4588","BK4585","002693","BK0239","IGF","GH","BK4196","BK4551"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0371},{"period":"1month","weight":0.0137},{"period":"3month","weight":0.0604},{"period":"6month","weight":0.1101},{"period":"1year","weight":0.2168},{"period":"ytd","weight":0.1762}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.529412,"avgChangeRate":-0.004463},{"month":2,"riseRate":0.705882,"avgChangeRate":-0.00609},{"month":3,"riseRate":0.764706,"avgChangeRate":0.012882},{"month":4,"riseRate":0.823529,"avgChangeRate":0.024338},{"month":5,"riseRate":0.470588,"avgChangeRate":0.003408},{"month":6,"riseRate":0.294118,"avgChangeRate":-0.019498},{"month":7,"riseRate":0.764706,"avgChangeRate":0.018575},{"month":8,"riseRate":0.470588,"avgChangeRate":-0.010146},{"month":9,"riseRate":0.411765,"avgChangeRate":-0.009834},{"month":10,"riseRate":0.588235,"avgChangeRate":0.00069},{"month":11,"riseRate":0.411765,"avgChangeRate":0.007759},{"month":12,"riseRate":0.5625,"avgChangeRate":0.003059}],"exchange":"ARCA","name":"全球基础设施ETF-iShares","nameEN":"iShares Global Infrastructure ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"全球基础设施ETF-iShares(IGF)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供全球基础设施ETF-iShares(IGF)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"全球基础设施ETF-iShares,IGF,全球基础设施ETF-iShares股票,全球基础设施ETF-iShares股票老虎,全球基础设施ETF-iShares股票老虎国际,全球基础设施ETF-iShares行情,全球基础设施ETF-iShares股票行情,全球基础设施ETF-iShares股价,全球基础设施ETF-iShares股市,全球基础设施ETF-iShares股票价格,全球基础设施ETF-iShares股票交易,全球基础设施ETF-iShares股票购买,全球基础设施ETF-iShares股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"全球基础设施ETF-iShares(IGF)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供全球基础设施ETF-iShares(IGF)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}